Skip to Content

'
Therese Bartholomew Bevers, M.D., F.A.A.F.P.

Present Title & Affiliation

Primary Appointment

Professor, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Medical Director, Cancer Prevention Center, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Medical Director, Prevention Outreach Programs, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

 

Therese B. Bevers, MD, is professor of Clinical Cancer Prevention and the medical director of the Cancer Prevention Center and prevention outreach programs at MD Anderson Cancer Center.

In her role as medical director, Dr. Bevers has overseen the growth and program development of the Cancer Prevention Center—the first comprehensive clinical cancer prevention service program in the country—since its opening in 1996.

Her clinical and research interests are in the area of breast cancer prevention, screening and diagnosis. She was the MD Anderson co-principal investigator (PI) on the groundbreaking Breast Cancer Prevention Trial which demonstrated that tamoxifen reduced the risk of developing breast cancer by one half and PI of the STAR trial which showed that raloxifene had similar benefits but fewer risks. She was the PI at MD Anderson for a study investigating whether polyphenon E, an active substance of green tea, benefits women at increased risk for breast cancer. She is also investigating the potential role of Vitamin D in breast cancer prevention. Dr. Bevers chairs the National Comprehensive Cancer Network’s guideline panels on Breast Cancer Screening and Diagnosis and Breast Cancer Risk Reduction. 

She is the recipient of many awards including the Julie and Ben Rogers Award for Excellence in Prevention in 2006, the Kathryn S. Stream Award for Excellence in Women’s Health in 2011 and the Faculty Achievement Award in Prevention in 2011. 

Research Interests

Breast cancer prevention, screening, diagnosis and survivorship

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler Street
P.O. Box 301439
Unit Number: 1322
Houston, TX 77230-1439
Phone: (713) 745-8048

Education & Training

Degree-Granting Education

1987 The University of Texas Health Science Center at San Antonio, San Antonio, TX, MD, Doctor of Medicine
1981 Texas Woman's University, Denton, TX, BS, Magna Cum Laude, Chemistry, Biology

Postgraduate Training

7/1987-6/1990 Family Practice Residency, The University of Texas Health Science Center at San Antonio, San Antonio, TX, Dr. J.J. Gaspard
6/1981-8/1982 Analytical Chemistry, Texas Woman's University, Denton, TX, Dr. Carlton Wendel

Board Certifications

7/2009 American Board of Family Practice

Experience/Service

Other Appointments/Responsibilities

Co-Director, Clinical Cancer Prevention Research Core, Duncan Family Institute for Cancer Prevention and Risk Assessment, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2010-present

Institutional Committee Activities

Founding Member, Center for Global Cancer Early Detection, 2013-present
Member, Lung Moonshot-Prevention and Early Detection, 2013-present
Member, Breast and Ovarian Moonshot, 2013-present
Member, Center for Energy Balance in Cancer Prevention and Survivorship Advisory Committee, 2013
Member, Search Committee, Division Head of Internal Medicine, 2013
Member, Patient History Database Data Access Committee, 2012-present
Chair, Clinical Cancer Prevention Clinical Research Meeting, 2012-present
Member, External Communications Advisory Committee, 2012-present
Co-Chair, Integrative Health Working Group, 2011-present
Member, Comprehensive Cancer Control-Survivorship Workgroup, 2011-present
Member, Duncan Family Institute Clinical Cancer Prevention Research Core Steering Committee, 2011-present
Member, Meaningful Use Steering Committee, 2011-present
Member, Comprehensive Cancer Control Planning and Implementation Workgroup, 2011-present
Member, Comprehensive Cancer Control-Liver Workgroup, 2011-present
Clinical Sponsor, Patient History Database Project, Phase II, 2011-present
Member, Integrative Cancer Medicine Steering Committee, 2010-present
Co-Chair, Comprehensive Cancer Control - Breast Workgroup, 2010-present
Member, Cancer Survivorship Textbook Workgroup, 2010-present
Member, Clinical Cancer Prevention Faculty Career Development and Promotion Committee, 2010-present
Member, PRS Executive Council, 2010-2013
Member, PRS Budget and Finance Committee, 2010-2012
Member, Duncan Family Institute for Cancer Prevention and Risk Assessment Executive Committee, 2009-present
Member, Cancer Survivorship Education Subcommittee, 2009-present
Member, Faculty Appeals Panel, 2009-present
Member, Duncan Family Institute Premalignant Genome Atlas Program Steering Committee, 2009-present
Member, Comprehensive Cancer Control Strategic Plan Steering Committee, 2008-present
Chair, Cancer Survivorship Community Health Professionals Subcommittee, 2007-present
Member, Breast Program Leadership Committee, 2006-present
Member, Cancer Survivorship Steering Committee, 2006-present
Member, Cancer Survivorship Clinical Care Workgroup, 2006-present
Member, Multidisciplinary Breast MRI Research Committee, 2006-present
Co-Chair, Multidisciplinary Clinical Management Conference for Benign Breast Lesions, 2004-present

Honors and Awards

2011 2011 Faculty Achievement Award in Cancer Prevention, The University of Texas MD Anderson Cancer Center
2011 Kathryn S. Stream Award for Excellence in Women's Health, The Women's Fund and The Texas Medical Center Women's Health Network
2011 Woman Leading the Way June 2011, Women Faculty Programs, The University of Texas MD Anderson Cancer Center
2009-2013 America's Top Doctors, U.S. News and World Report
2009-2010 Who's Who in Medicine and Healthcare
2008 Who's Who in America
2006-2007 The Julie and Ben Rogers Award for Excellence in Prevention, The University of Texas MD Anderson Cancer Center
2006 America's Top Doctors, U.S. News and World Report
2004-2007 Who's Who in Medicine and Healthcare
2004-2005 Who's Who in the World
2000-2004 Who's Who in America
2000-2001 Who's Who in the World
1998-2000 Who's Who in Medicine and Healthcare
1997 Physician of the Day, Seventy-fifth Texas Legislature, January 30,
1987-1988 Distinguished Family Practice Resident, The University of Texas Health Science Center at San Antonio
1984-1985 Notable Women of Texas

Professional Memberships

Action Plan on Breast and Cervical Cancer for the State of Texas
Member, Steering Committee, 2003
Alliance for Clinical Trials in Oncology
Member, Cancer Control Program Prevention Committee, 2012-2014
Member, 2011-present
American Academy of Family Physicians
Member, 1987-present
American Association for Cancer Research
Member, 2011-present
American Cancer Society
Member, Leadership Council (Gulf Coast Region), 2010-present
Co-chair, Leadership Council (Gulf Coast Region), 2010-2011
Chair, Vision 2015 Council (Gulf Coast Region), 2006-2007
Member, Board Ends Committee (High Plains Division), 2005-2010
Member, Board of Directors (High Plains Division), 2005-2010
Member, Vision 2015 Council (Gulf Coast Region), 2005-2010
President, Executive Council (Gulf Coast Region), 2005-2009
Chair, Breast Cancer Detection Committee (Texas Division), 2005
Chair, Nominations Committee (Texas Division), 2004-2005
President, Executive Board (Houston Metro), 2004-2005
Member, Board of Directors (Texas Division), 2002-2005
Member, Health Initiatives Council (Houston Metro), 2002-2005
Member, Health Science Advisory Committee (Texas Divison), 2002-2005
Member, Nominations Committee (Texas Division), 2002-2005
Vice President, Executive Board (Houston Metro), 2002-2004
Member, Breast Cancer Detection Committee (Texas Division), 2000-2005
Member, Colorectal Cancer Detection Committee (Texas Division), 2000-2005
Member, Executive Board (Houston Metro), 2000-2005
Member, Cancer Control Council (Houston Metro), 2000-2002
American Cancer Society Cancer Action Network
Member, Policy Review Group, Transforming Prevention in the American Health Care System, Washington, DC, 2008
Team Leader, Ambassador Constituent Team, 2007-2009
Ambassador, Celebration on the Hill, Washington, DC, 2006
Ambassador, Celebration on the Hill, Washington, DC, 2002
American Medical Association
Member, 1997-present
American Society of Breast Disease
Member, Consensus Committee, 2006-2011
Member, 2005-present
American Society of Clinical Oncology
Member, 2005-present
Member, Reimbursement for Cancer Prevention Services Subcommittee, 2005-2006
American Society of Preventive Oncology
Member, 2005-present
Association of Governing Boards of Universities and Colleges
Member, 2001-2007
Avon Foundation
Member, Houston Breast Cancer Task Force, 2008-2010
Breast Health Collaborative of Texas
Member, 2010-present
Harris County Medical Society
Member, 1997-present
National Comprehensive Cancer Network
Chair, Breast Cancer Risk Reduction Guideline Panel, 2005-present
Chair, Breast Cancer Screening & Diagnostic Guideline Panel, 2003-present
Member, Breast Cancer Risk Reduction Guideline Panel, 1999-present
Member, Breast Cancer Screening & Diagnostic Guideline Panel, 1997-present
National Surgical Adjuvant Breast and Bowel Project
Member, Steering Committee, A study to evaluate different decision-making approaches used by women known to be at high risk for breast cancer, 2009-present
Member, Board of Directors, 2007-2010
Oregon Evidence-based Practice Center
Panel Member, Future Research Agenda: Reducing the Risk of Breast Cancer, 7/2010
Southwest Oncology Group
Member, 2011-present
Texas Academy of Family Physicians
Co-Chair, Commission on Public Health, Research & Clinical Affairs, 1998-2000
Co-Chair, Clinical Preventive Medicine Committee, 1997-1998
Member, Clinical Preventive Medicine Committee, 1996-1998
Chair, Health Care Services Committee, 1995-1996
Member, Bylaws Committee, 1992-1996
Member, Health Care Services Committee, 1992-1996
Member, 1987-present
Texas Cancer Plan
Member, Executive Steering Committee, 2004
Texas Medical Association
Member, Task Force on Prevention, 1997-2000
Member, 1996-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Middleton LP, Sneige N, Coyne R, Shen Yu, Dong W, Dempsey P, Bevers TB. Most lobular carcinoma in situ and atypical lobular hyperplasia diagnosed on core needle biopsy can be managed clinically with radiologic follow-up in a multidisciplinary setting. Cancer Medicine, 6/2014. PMID: 24639339.
2. Volk RJ, Linder SK, Leal VB, Rabius V, Cinciripini PM, Kamath GR, Munden RF, Bevers TB. Feasibility of a patient decision aid about lung cancer screening with low-dose computed tomography. Preventive Medicine(62):60-63, 5/2014. PMID: 24518006.
3. Crew KD, Ho KA, Brown P, Greenlee H, Bevers TB, Arun B, Sneige N, Hudis C, McArthur HL, Chang J, Rimawi M, Cornelison TL, Cardelli J, Santella RM, Wang A, Lippman SM, Hershman DL. Effects of a green tea extract, polyphenon E, on systemic biomarkers of growth factor signaling in women with hormone receptor-negative breast cancer. Journal of Human Nutrition and Dietetics, 3/2014.
4. Nayak A, Carkaci S, Gilcrease MZ, Liu P, Middleton LP, Bassett RL, Zhang J, Zhang H, Coyne RL, Bevers TB, Sneige N, Huo L. Benign papillomas without atypia diagnosed on core needle biopsy: experience from a single institution and proposed criteria for excision. Clin Breast Cancer 13(6):1-11, 12/2013. e-Pub 10/2013. PMID: 24119786.
5. Versace F, Engelmann JM, Jackson EF, Slapin A, Cortese KM, Bevers TB, Schover LR. Brain responses to erotic and other emotional stimuli in breast cancer survivors with and without distress about low sexual desire: a preliminary fMRI study. Brain Imaging Behav 7(4):533-42, 12/2013. PMID: 23955492.
6. Yahalom G, Weiss D, Novikov I, Bevers TB, Radvanyi LG, Liu M, Piura B, Iacobelli S, Sandri MT, Cassano E, Allweis TM, Bitterman A, Engelman P, Vence LM, Rosenberg MM. An antibody-based blood test utilizing a panel of biomarkers as a new method for improved breast cancer diagnosis. Biomark Cancer 5:71-80, 11/2013. PMCID: PMC3855201.
7. Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer 119(19):3454-61, 10/2013. e-Pub 8/2013. PMID: 23983047.
8. Reddy N, Ninan T, Tabar L, Bevers T. The results of a breast cancer screening camp at a district level in rural India. Asian Pacific J Cancer Prev. e-Pub 3/2013.
9. Guo M, Gong Y, Wang J, Dawlett M, Patel S, Liu P, Bevers TB, Sneige N. The role of human papillomavirus type 16/18 genotyping in predicting high-grade cervical/vaginal intraepithelial neoplasm in women with mildly abnormal Papanicolaou results. Cancer Cytopathol 121(2):79-85, 2/2013. e-Pub 12/2012. PMID: 23225501.
10. Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DL. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila) 5(9):1144-54, 9/2012. e-Pub 7/2012. PMCID: PMC3816771.
11. Mazouni C, Sneige N, Rouzier R, Balleyguier C, Bevers T, André F, Vielh P, Delaloge S. A nomogram to predict for malignant diagnosis of BI-RADS Category 4 breast lesions. J Surg Oncol 102(3):220-4, 9/2010. PMID: 20740578.
12. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N. Update of the NSABP Study of Tamoxifen and Raloxifene (STAR). Cancer Prev Res (Phila Pa) 3(6):696-706, 6/2010. PMCID: PMC2935331.
13. Espeland MA, Shumaker SA, Limacher M, Rapp SR, Bevers TB, Barad DH, Coker LH, Gaussoin SA, Stefanick ML, Lane DS, Maki PM, Resnick SM for the WHIMS and CoSTAR Study Groups. Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition. Journal of Women's Health 19(3):371-9, 2010. PMCID: PMC2867626.
14. Legault C, Maki PM, Resnick SM, Coker L, Hogan P, Bevers TB, Shumaker SA. Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene. J Clin Oncol 27(31):5144-52, 2009. PMCID: PMC2773473.
15. Cyrus-David M, King J, Bevers T, Robinson E. Validity assessment of the Breast Cancer Risk Reduction Health Belief scale. Cancer 115(21):4907-16, 2009. PMCID: PMC2768118.
16. Lu J, Wei Q, Bondy ML, Brewster AM, Bevers TB, Yu TK, Buchholz TA, Meric-Bernstam F, Hunt KK, Singletary SE, Wang LE. Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged </=55 years. Breast Cancer Res Treat 110(2):357-66, 7/2008. PMCID: PMC3030478.
17. Dong W, Berry DA, Bevers TB, Kau SW, Hsu L, Theriault RL, Shen Y. Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: The University of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev 17(5):1096-103, 5/2008. PMCID: PMC2701362.
18. Guo M, Patel SJ, Chovanec M, Jan YJ, Tarco E, Bevers TB, Anderson K, Sneige N. A human papillomavirus testing system in women with abnormal Pap results: a comparison study with follow-up biopsies. Acta Cytol 51(5):749-54, Sep-Oct, 9/2007. PMID: 17910345.
19. Shen Y, Dong W, Esteva FJ, Kau SW, Theriault RL, Bevers TB. Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center? Breast Cancer Res Treat 102:347-56, 2006. PMID: 17028980.
20. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, Wolmark N. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23):2727-41, 2006. PMID: 16754727.
21. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652-62, 11/2005. PMID: 16288118.
22. Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, Hsu L, Krishnamurthy S, Theriault RL, Hortobagyi GN. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 103(6):1122-8, 3/2005. PMID: 15712375.
23. Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhingran A, Wharton JT, Eifel P, Bevers TB, Levenback CF, Gershenson DM, Bodurka DC. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol 23(30):7428 -36, 2005. PMID: 16234510.
24. Singletary SE, Atkinson EN, Hoque A, Sneige N, Sahin AA, Fritsche HA, Jr, Lotan R, Lu T, Hittelman WN, Bevers TB, Stelling CB, Lippman SM. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res 8:2835-42, 9/2002. PMID: 12231524.
25. Singletary, SE, Lieberman R, Atkinson N, Sneige N, Sahin A, Tolley S, Colchin M, Bevers T, Stelling C, Fornage B, Fritsche H, Hittelman W, Kelloff G, Lippman SM. Novel translational model for breast cancer chemoprevention study: Accrual to a presurgical intervention with tamoxifen and N-[4-Hydroxyphenyl] retinamide. Cancer Epidemiology, Biomarkers and Prevention. 9:1087-1090, 5/2000.

Invited Articles

1. Litton JK, Bevers TB, Arun BK. Exemestane in the prevention setting. Ther Adv Med Oncol 4(3):107-12, 5/2012. PMCID: PMC3349074.
2. Krishnamurthy S, Bevers T, Kuerer H, Yang WT. Multidisciplinary considerations in the management of high-risk breast lesions. AJR Am J Roentgenol 198(2):W132-40, 2/2012. PMID: 22268202.
3. Bevers TB. Breast Cancer Prevention: An Update of the STAR Trial. Curr Treat Options Oncol 11(3):66-9, 12/2010. PMID: 21061192.
4. Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Meszoely I, Newman L, Pritchard E, Seewaldt V, Sellin RV, Shapiro CL, Ward JH. National Comprehensive Cancer Network clinical practice guidelines in oncology: breast cancer risk reduction. J Natl Compr Canc Netw 8(10):1112-46, 11/2010. PMID: 20971838.
5. Bevers TB. Alcohol and Cancer Incidence in Women. Curr Oncol Rep 11(6):417-419, 11/2009. PMID: 19840518.
6. Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Heerdt AS, Helvie M, Huff JG, Khakpour N, Khan SA, Krontiras H, Lyman G, Rafferty E, Shaw S, Smith ML, Tsangaris TN, Williams C, Yaneeklov T. National Comprehensive Cancer Network clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw 7(10):1060-96, 11/2009. PMID: 19930975.
7. Mahoney MC, Bevers T, Linos E, Willett WC. Opportunities and strategies for breast cancer prevention through risk reduction. CA Cancer J Clin 58(6):347-371., Nov-Dec, 11/2008. e-Pub 11/2008. PMID: 18981297.
8. Bevers TB. Ultrasound for the screening of breast cancer. Curr Oncol Rep 10(6):527-8, 11/2008. PMID: 18928668.
9. Bevers TB. Raloxifene: An agent for breast cancer prevention. Expert Rev Obstet Gynecol 3(3):277-85., 2008.
10. Bevers TB. CT screening for lung cancer. Curr Oncol Rep 9(6):501-2, 11/2007. PMID: 17991359.
11. Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Lawton T, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Seewaldt V, Sellin RV, Shapiro CL, Singletary E, Ward JH, Ward JH. National Comprehensive Cancer Network clinical practice guidelines in oncology: breast cancer risk reduction. J Natl Compr Canc Netw 5(8):676-701, 9/2007. PMID: 17927926.
12. Bevers TB. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women. J Natl Compr Canc Netw 5(8):719-24, 9/2007. PMID: 17927929.
13. Bevers TB. Raloxifene and the prevention of breast cancer. Expert Opin Pharmacother 7(16):2301-07, 2006. PMID: 17059385.
14. Umezu-Goto M, Tanyi J, Lahad J, Liu S, Yu S, Lapushin R, Hasegawa Y, Lu Y, Trost R, Bevers T, Jonasch E, Aldape K, Liu J, James RD, Ferguson CG, Xu Y, Prestwich GD, Mills GB. Lysophosphatidic acid production and action: Validated targets in cancer? J Cell Biochem 92(6):1115-40, 9/2004. PMID: 15258897.
15. Bevers TB, Anderson BO, Bonaccio E, Borgen PI, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Helvie M, Hoover S, Krontiras H, Shaw S, Singletary E, Sugg Skinner C, Smith ML, Tsangaris TN, Wiley EL, Williams C, Williams C. National Comprehensive Cancer Network clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw 1(5):242-263, 5/2003. PMID: 16687096.
16. Bevers TB. Breast cancer chemoprevention: current clinical practice and future direction. Biomed Pharmacother 55:559-564, 2001.
17. Carlson, R, Barakat R, Bevers T, Daly MB, Edge S, Garber JE, Gradishar W, Mahoney M, Sellin RV, Shapiro C, Singletary E, Theriault R, Ward J, Whittemore A, Williams C, Winer E. NCCN Practice Guideline: Breast Cancer Risk-Reduction. Oncology 13:241-254, 11/1999.
18. Bevers T. Evidence-based Cancer Screening. Highlights Oncol Pract 16:91-99, 3/1999.
19. Bevers T. How to Perform an Adequate Clinical Breast Examination: A Photographic Guide. Primary Care and Cancer, 3/1999.
20. Singletary, SE, Bevers T, Dempsey P, Farrar B, Garber J, Harris R, Helvie M, Jacobs M, Pass H, Patterson Smith ML, Tarantolo S, Venta LA. NCCN Practice Guideline: Screening for and Evaluation of Suspicious Breast Lesions. Oncology 12:89-138, 11/1998.

Editorials

1. Bevers TBl Lippman, SM. Randomized trial of breast self-examination in Shanghai: Methodology and preliminary results. Breast Disease: A YearBook Quarterly 8:308-309, 1998.
2. Bevers TB. Breast self-examination an optional screening modality in national comprehensive cancer network breast cancer screening guidelines. Breast Diseases: A YearBook Quarterly 9:230-31, 1998.
3. Bevers TB. Raloxifene: A new paradigm for breast cancer prevention. Breast Diseases: A YearBook Quarterly 18:24-5, 4/2007.
4. Bevers TB. Breast awareness: A shift in the paradigm of breast self-examination. J Natl Compr Canc Netw 7(10):1042-3, 11/2009. PMID: 19930973.

Abstracts

1. Ganesan N, Bevers T, Ying J, Coyne R, Lane D, Albarracin, Bedrosian I. Risk of breast cancer in women observed after core biopsy diagnosis of atypical ductal hyperplasia. Society of Surgical Oncology 67th Annual Cancer Symposium, Phoenix, AZ, 3/2014.
2. Volk RJ, Linder SK, Leal VB, Rabius V, Cinciripini PM, Kamath GR, Munden RF, Bevers TB. Patients' reactions to a decision aid about lung cancer screening with low-dose spiral computed tomography: An uncontrolled trial. 2013 International Shared Decision Making Conference, Lima, Peru (#1564), 6/2013.
3. Volk RJ, Linder SK, Leal VB, Rabius V, Cinciripini PM, Kamath GR, Munden RF, Bevers TB. Patients' reactions to a decision aid about lung cancer screening with low-dose spiral computed tomography: an uncontrolled trial. J Clin Oncol 31(suppl; abstr 1564), 2013.
4. Nimmons S, Bambhroliya A, Bevers T, Ying J, Brown P, Cook E, Newman L, Brewster A. The evaluation of breast cancer chemoprevention uptake in a high-risk cohort. AACR Frontiers of Cancer Prevention Meeting, 2013.
5. Wang J, Kologinczak T, Dawlett M, Bevers T, Sneige N, Guo M. Risk of CIN2+ in women 30 Years and older with negative pap and positive hybrid capture 2 HPV DNA testing results. Journal of the American Society of Cytopathology 1(1):S52, 11/2012.
6. Dawlett M, Kologinczak T, Wang J, Sneige N, Bevers T, Guo M. Three-year follow-up for women 30 years and older with negative pap and negative hybrid capture 2 HPV DNA testing results. Journal of the American Society of Cytopathology 1(1):S40, 11/2012.
7. Linder SK, Nelson BM, Leal VB, Kamath, GR, Bevers TB, Munden RF, Rabius VA, Cinciripini PM, Volk RJ. Acceptability of a patient decision aid for lung cancer screening. 2012 Cancer Prevention Research Institute of Texas (CPRIT), 10/2012.
8. Foxhall LE, Bevers TB, Woods KV, Polansky M. An integrated professional oncology curriculum for Texas primary care professionals: improving care and enhancing quality of life for breast, colon and prostate cancer survivors. 2012 Cancer Prevention Research Institute of Texas (CPRIT), 10/2012.
9. Bedi D, Patnana M, Lu K, Hernandez M, Bevers T, Bast R. Ovarian cancer screening with CA 125 and selective use of ultrasound: sonographic findings. American Roentgen Ray Society (#1147), 5/2012.
10. Versace F, Schover LR, Engelmann JM, Jackson EF, Bevers TB, Morrow PK. Impact of past chemotherapy on emotional processing: an fMRI study in breast cancer survivors. 2012 Cancer Survivorship Research Retreat, 1/2012.
11. Raju GS, Walker LK, Vadyala V, Krishna SG, Mahometano L, Bevers TB, Vining DJ, Wu X, Hawk E. “Adenoma detection rates” - How far can we push the envelope?. Gastrointestinal Endoscopy (#292), 2012.
12. Crew KD, Ho KA, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, chang J, Rimawi M, Vornik L, cornelison TL, Cardelli J, Santella RM, Wang A, Lippman SM, Hershman DL. Biomarker effects of an oral green tea extract, Polyphenon E, in women with a history of hormone receptor-negative breast cancer. American Association for Cancer Research Frontiers in Cancer Prevention Research, Anaheim, CA, 2012.
13. Nelson BM, Classen L, Volk RJ, Bevers TB. Development and implementation of a video-based decision aid for lung cancer screening. 2011 Cancer Prevention Research Institute of Texas (CPRIT), 11/2011.
14. Crew KD, Lippman S, Hershman DL, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArhtur H, Vornik L, Cornelison T. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of Polyphenon E in women with a history of hormone receptor-negative breast cancer. Cancer Prevention Research 4(10 Supplement):CN06-02, 10/2011.
15. Bevers T. Phase IB randomized, double-blinded, placebo-controlled, dose-escalation study of Polyphenon E in women with a history of hormone receptor-negative breast cancer. AACR Frontiersin Cancer Prevention (#CN06-02), 10/2011.
16. Polansky M, Woods K, Bevers TB, Foxhall L. An integrated professional oncology curriculum for primary care professionals: improving care and enhancing quality of life for breast, colon and prostate cancer survivors. American Academy of Physician Assistants 39th Annual Physician Assistant Conference, Las Vegas, NV, 5/2011.
17. Foxhall, LE, Bevers,T, Polansky, M, Woods, K. A cancer survivorship management rotation for primary care trainees. The University of Texas Academy of Health Science Education 7th Annual Innovations in Health Education Conference, 2/2011.
18. Polansky M, Woods K, Bevers TB, Foxhall L. An integrated professional oncology curriculum for primary care professionals: improving care and enhancing quality of life for breast, colon and prostate cancer survivors. Texas Association of Physician Assistants Annual Conference, San Antonio, TX, 2/2011.
19. Morrow PKH, Bevers TB, Zandstra F, Russell L. Multidisciplinary care of the breast cancer survivor: an innovative approach. Breast Cancer Symposium. J Clin Oncol 29(suppl 27; abstr 206), 2011.
20. Crew KD, Ippolito P, Brown P, Greenlee H, Bevers T, Arun B, Hudis C, McArthur HL, Vornik L, Cornelison TL, Lippman SM, Hershman DL. Quality of life in a chemoprevention trial of an oral green tea extract among women with hormone receptor-negative breast cancer. American Society of Preventive Oncology Annual Meeting, 2011.
21. Cyrus-David M, Bevers T, Wang W, Basen-Engquist K. The willingness to accept chemoprevention strategies by women at increased risk of breast cancer. AACR International Conference on Frontiers in Cancer Prevention Research (#PR-08), 7/2010.
22. Lu KH, Skates S, Bevers TB, Newland W, Moore RG, Leeds L, Harris S, Adeyinka OW, Fritshe HA, Bast RC. A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA). J Clin Oncol (ASCO Meeting Abstracts) 28:No. 15_suppl(May 20 Supplement) (#5003), 2010.
23. Foxhall L, Polansky M, Woods K, Bevers T. An integrated professional oncology curriculum for Texas primary care professionals: Improving care and enhancing quality of life for breast, colon and prostate cancer survivors. 2010 Cancer Prevention Research Institute of Texas (CPRIT) (#353), 2010.
24. Shea L, Bevers T, Espat A, Kim S, Rigby E, Ward J. Cancer risk check offers a personalized feedback based on individual cancer risk. 2010 Cancer Prevention & Research Institute of Texas (CPRIT) (#376), 2010.
25. Crew KD, Brown P, Greenlee H, Bevers T, Arun B, Hudis C, McArthur HL, Vornik L, Cornelison TL, Hershman DL. Phase IB randomized, double-blinded, placebo-controlled, dose-escalation study of polyphenon E in women with a history of hormone receptor-negative breast cancer. J Clin Oncol 28:15s (#TPS142), 2010.
26. Dawlett M, Wang J, Patel S, Gong Y, Bevers T, Sneige N, Guo M. Co-screening women 30 years of age and older using hybrid capture® 2 HPV DNA testing and pap cytology: 2-year experience in a cancer prevention center. The 57th Annual Scientific Meeting of the American Society of Cytopathology, Denver, CO, 11/2009.
27. Olson AL, T. Bevers, Guzman M, Theriault RL, Hortobagyi GN, Hahn KM. Cervical and colorectal cancer screening among breast cancer (BrCa) survivors followed in either a breast center (BC) or a breast survivorship clinic (SvC) at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol (ASCO Meeting Abstracts) 27:No. 15S(May 20 Supplement) (#e20506), 2009.
28. Guo M, Gong Y, Dawlett M, Patel S, Bevers T, Sneige N. HPV DNA co-screening with pap cytology in women age 30 and older in a Cancer Prevention Center. The 55th Annual Scientific Meeting of the American Society of Cytopathology, Houston, TX, 11/2007.
29. Johnson CM, Ensor J, Broglio K, Smolenski D, Ravdin P, Amos C, Meric-Bernstam F, Brewster A, Bevers T, Arun B, Berry D. Building a predictive breast cancer risk model. AMIA Annu Symp Proc:995, 2007. PMID: 18694095.
30. Dong W, Berry D, Bevers T, Kau Shu-Wan, Hsu L, Theriault R, Shen Y. Prognostic role of detection method in breast cancer: M.D. Anderson Cancer Center experience. Proceedings of the American Association for Cancer Research Meeting, Los Angeles, 2007.
31. Barad DH, Bevers TB, Coker LH, Espeland MA, Jaramillo SA, Limacher M, Lane DS, Maki P, Rapp S, Resnick S, Shumaker SA, Stefanick ML. Relative effects of tamoxifen, raloxifene, and estrogen therapy on cognition: results from the Women's Health Initiative Study of Cognitive Aging (WHISCA) and the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) clinical trials. Society for Gynecologic Investigation, 2007.
32. Wickerham DL, Constantino JP, Vogel V, Cronin W, Cecchini R, Atkins J, Bevers T et al. The study of tamoxifen and raloxifene (STAR): initial findings from the NSABP P-2 breast cancer prevention study. J Clin Oncol (ASCO Meeting Abstracts) 24:No. 18S(June 20 Supplement) (#LBA5), 2006.
33. Cristofanilli, M, Yamamura Y, Kau SW, Bevers TB, Strom SS, Patangan MG, Hsu LM, Krishnamurthy S, Hortobagyi GN. Thyroid hormones and breast cancer: primary hypothyroidism is associated with a reduced incidence of primary breast cancer. Proceedings of the American Association for Cancer Research 44:66, 11/2003.
34. Sun, CC, Bodurka DC, Lu KH, Efron B, Andersen R, Bevers TB, Gershenson DM, Bast RC. Perceptions of OVCA risk and screening: differences between women with a history of breast cancer (WHxBr) and women with no history of breast cancer (WnoBr). Gynecol Oncol, 88:239, 9/2003.
35. Boling, W, Carmack Taylor CL, Shinn EH, Dijk F, Zilstra R, Bevers TB, Basen-Engquist K. Breast cancer survivors and physical activity: Accuracy of self-report with surgeon general’s recommendations. Annals of Behavioral Medicine 24:S163, 11/2002.
36. Wang, S, Bevers TB, Krishnamurthy S. Changes in cervicovaginal smears of women receiving tamoxifen for chemoprevention of breast cancer compared with those of women taking placebo. Mod Path 15:91A (#372), 9/2002.
37. Singletary, SE, Lieberman R, Binkley S, Atkinson EN, Sneige N, Sahin A, Bevers T, Stelling c, Fornage B, Fritsche H, Hittelman W, Kelloff GJ, Lippman SM. Novel translational model for breast cancer chemoprevention study: presurgical intervention with tamoxifen and 4-HPR. Proceedings of the American Society of Clinical Oncology, 35th Annual Meeting, Atlanta, GA,:84a (#317), 5/1999.
38. Atkinson R, Symmans F, Bevers T, Woodward W, Brewster. Prevalence of breast stem cells in high risk benign breast lesions and association with breast feeding. American Association for Cancer Research. Submitted.

Book Chapters

1. Bevers T, Brown PH, Maresso KC, Hawk ET. Cancer Prevention, Screening and Early Detection. In: Abeloff's Clinical Oncology, Fifth Edition. Ed(s) Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE. Elsevier: Philadelphia, PA, 322-59, 2014. ISBN: 978-1-4557-2865-7.
2. Bevers T. Breast Self-Examination: A Changing Paradigm. In: Advanced Therapy of Breast Disease, Third Edition. Ed(s) Babiera BV, Skoracki RJ, Esteva FJ. People's Medical Publishing House: Shelton, CT, 139-52, 2012.
3. Bevers TB. Chapter 86: Clinical Management of the Patient at Increased or High Risk. In: The Breast: Comprehensive Management of Benign and Malignant Diseases, Fourth Edition. Ed(s) Bland KI, Copeland EM. Saunders: Philadelphia, PA, 1381-92, 2009. ISBN: 978-1-4160-5221-0.
4. Bevers T, Bedrosian I. Chapter 72: Prevention: Prophylactic Mastectomy and Chemoprevention. In: Advanced Therapy for Surgical Oncology. Ed(s) Pollock R, Curley S, Ross M, Perrier N. BC Decker, Inc: Hamilton, Ontario, Canada, 588-96, 2008.
5. Bevers TB. Primary Prevention and Screening for the Early Detection of Breast Cancer. In: Breast Cancer. M.D. Anderson Cancer Center. Ed(s) Hunt KK, Robb GL, Strom EA, Ueno NT. Springer-Verlag: New York, 27-55, 2007.
6. Bevers T. Breast Self-examination. In: Advanced Therapy of Breast Disease, Second Edition. Ed(s) Singletary SE, Robb GL, Hortobagyi GN. B.C. Decker, Inc.,, 193-201, 2004.
7. Coyne RL, Bevers T. Counseling about Risk Management. In: Handbook of Breast Cancer Risk Assessment: Evidence-based guidelines for evaluation, prevention, counseling, and management. Ed(s) Vogel VG, Bevers T. Jones and Bartlett Publishers: Sudbury, Mass, 126-45, 2003.
8. Mizell V, Bevers T. Development of a Risk Assessment Clinic. In: Handbook of Breast Cancer Risk Assessment: Evidence-based guidelines for evaluation, prevention, counseling, and managemen. Ed(s) Vogel VG, Bevers T. Jones and Bartlett Publishers: Sudbury, Mass, 41-54, 2003.
9. Lazzaro MV, Bevers T. Hormone Replacement Therapy. In: Handbook of Breast Cancer Risk Assessment: Evidence-based guidelines for evaluation, prevention, counseling, and management. Ed(s) Vogel VG, Bevers T. Jones and Bartlett Publisher: Sudbury, Mass, 99-118, 2003.
10. Bevers T. Primary Prevention and Screening for the Early Detection of Breast Cancer. In: M.D. Anderson Cancer Care Series. Ed(s) Hunt KK, Robb GL, Strom EA, Ueno NT. Springer-Verlag: New York, 21-54, 2001.
11. Bevers T. Diagnosis of Palpable Breast Masses. In: Advanced Therapy of Breast Disease, First Edition. Ed(s) Singletary SE, Robb GL. B. C. Decker, Inc. Hamilton Ontario, 73-82, 2000.
12. Bevers T, Levin BL. Colorectal Cancer: Population Screening and Surveillance. In: Evidence Based Gastroenterology and Hepatology. Ed(s) JW McDonald, AK Burroughs, BG Feagan, ed. BMJ Books: London, 230-240, 1999.

Books (edited and written)

1. Vogel VG, Bevers T, Editors. Handbook of breast cancer risk assessment: Evidence-based guidelines for evaluation, prevention, counseling, and management. Jones and Bartlett Publishers: Sudbury, Mass, 2003.

Letters to the Editor

1. Mac Bride MB, Pruthi S, Bevers T. The evolution of breast self-examination to breast awareness. Breast J 18(6):641-643, http://onlinelibrary.wiley.com/doi/10.1111/tbj.12023/abstract, Nov-Dec, 11/2012. e-Pub 9/26/2012. PMID: 23009674.

Manuals, Teaching Aids, Other Teaching Publications

1. Baldwin, D, Bevers T, Drugary M, Gullatte MM, Dow KH, Kaur J, O’Donnell J, Palos G, Phillips J. Competencies for Health Professionals: A multicultural perspective in the promotion of breast, cervical, colorectal and skin health. American Nurses Association, Washington, D.C, 3/1996.

Grant & Contract Support

Title: Promoting Informed Decisions about Lung Cancer Screening
Funding Source: Patient Centered Outcomes Research Institute
Role: Co-Principal Investigator
Principal Investigator: Robert Volk
Duration: 5/1/2014 - 4/30/2017
 
Title: Promoting Informed Decisions about Lung Cancer Screening
Funding Source: Patient Centered Outcomes Research Institute
Role: Co-Principal Investigator
Principal Investigator: Volk
Duration: 7/1/2013 - 6/1/2017
 
Title: Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Principal Investigator: Palomares
Duration: 6/1/2013 - 5/31/2014
 
Title: Patient Centered Outcome Research in the Elderly
Funding Source: The University of Texas Medical Branch at Galveston
Role: Co-Principal Investigator
Principal Investigator: Robert Volk
Duration: 5/1/2013 - 4/30/2018
 
Title: Blood Test for Breast Cancer Associated Auto Antibodies
Funding Source: Eventus Diagnostics, Inc.
Role: Principal Investigator-MDACC
Duration: 1/1/2013 - 12/31/2013
 
Title: A Randomized Double-Blind Placebo Controlled Biomarker Modulation Study of High Dose Vitamin D in Premenopausal Women at High Risk for Breast Cancer Phase IIB
Funding Source: SWOG
Role: Principal Investigator-MDACC
Duration: 7/1/2012 - 12/31/2015
 
Title: Vitamin D and Breast Cancer Biomarkers
Funding Source: Alliance
Role: Principal Investigator-MDACC
Duration: 7/2012 - 6/2014
 
Title: The Use of Simulated Whole Saliva as a Diagnostic Test for the Detection of Breast Cancer
Funding Source: University of Texas Dental Branch-Houston
Role: Collaborator
Principal Investigator: Jennifer Litton
Duration: 1/2/2011 - 6/30/2011
 
Title: The Use of Saliva as Diagnostic Fluid for the Detection of Breast Cancer in Women
Funding Source: Assurance Biosciences, Incorporated
Role: Principal Investigator
Duration: 1/1/2011 - 12/31/2012
 
Title: An Integrated Professional Oncology Curriculum for Texas Primary Care Professionals: Improving Care and Enhancing Quality of Life for Breast, Colon and Prostate Cancer Survivors
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Collaborator
Principal Investigator: Lewis Foxhall
Duration: 8/2010 - 1/31/2013
 
Title: Statistical Methods for Breast Cancer Prevention and Treatment Studies and Therapeutic Response
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Yu Shen
Duration: 6/16/2010 - 4/30/2015
 
Title: Using Multimedia Approaches to Communicate Probabilities in Patient Decision Aids for Low-Literacy Populations: Randomized Trial
Funding Source: Foundation for Informed Medical Decision Making-(FIMDM)
Role: Co-Investigator
Principal Investigator: Robert Volk
Duration: 5/15/2010 - 2/14/2013
 
Title: The Use of Stimulated Whole Saliva as a Diagnostic Test for the Detection of Breast Cancer in Women
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Co-Principal Investigator
Principal Investigator: Jennifer Litton
Duration: 6/1/2009 - 10/30/2010
 
Title: Phase IB Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women With a History of Hormone Receptor-Negative Breast Cancer
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Principal Investigator: Powel Brown
Duration: 9/30/2006 - 9/30/2012
 
Title: Effects of Selective Estrogen Receptor Modulators on Cognitive Aging: Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR)
Funding Source: NSABP
Role: Principal Investigator-MDACC
Duration: 2001 - 2008
 
Title: STAR Community Outreach Coordinator
Funding Source: NSABP
Role: Principal Investigator
Duration: 2000 - 2005
 
Title: Early Detection of Epithelial Ovarian Cancer
Funding Source: National Cancer Institute-DHHS-NIH-P50
Role: Collaborator
Principal Investigator: Robert Bast
Duration: 9/30/1999 - 8/31/2010
 
Title: Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Funding Source: NSABP
Role: Principal Investigator-MDACC
Duration: 1/1/1999 - 5/31/2012

Last updated: 6/11/2014